Literature DB >> 25802326

Panobinostat approved for multiple myeloma.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25802326     DOI： 10.1158/2159-8290.CD-NB2015-040

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


× No keyword cloud information.
  9 in total

1.  Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.

Authors:  Jeremy J McGuire; Niveditha Nerlakanti; Chen Hao Lo; Marilena Tauro; Thomas J Utset-Ward; Damon R Reed; Conor C Lynch
Journal:  Int J Cancer       Date:  2020-06-29       Impact factor: 7.396

2.  RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.

Authors:  Laura A Marlow; Ilah Bok; Robert C Smallridge; John A Copland
Journal:  Endocr Relat Cancer       Date:  2015-07-23       Impact factor: 5.678

3.  Histone deacetylase inhibitor NaBut suppresses cell proliferation and induces apoptosis by targeting p21 in multiple myeloma.

Authors:  Ruosi Yao; Danyang Han; Xiaoyang Sun; Chunling Fu; Qingyun Wu; Yao Yao; Hujun Li; Zhenyu Li; Kailin Xu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 4.  Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.

Authors:  Tianshu Yang; Yunkai Yang; Yan Wang
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

Review 5.  HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.

Authors:  Xing Lyu; Min Hu; Jieting Peng; Xiangyu Zhang; Yan Y Sanders
Journal:  Ther Adv Chronic Dis       Date:  2019-07-18       Impact factor: 4.970

6.  Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer.

Authors:  Arup Bag; Andrew Schultz; Saloni Bhimani; Olya Stringfield; William Dominguez; Qianxing Mo; Ling Cen; Dennis Adeegbe
Journal:  Oncoimmunology       Date:  2022-02-22       Impact factor: 7.723

7.  Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

Authors:  Manuela Terranova-Barberio; Maria Serena Roca; Andrea Ilaria Zotti; Alessandra Leone; Francesca Bruzzese; Carlo Vitagliano; Giosuè Scogliamiglio; Domenico Russo; Giovanni D'Angelo; Renato Franco; Alfredo Budillon; Elena Di Gennaro
Journal:  Oncotarget       Date:  2016-02-16

8.  Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.

Authors:  Shinji Takeuchi; Tetsunari Hase; Shinobu Shimizu; Masahiko Ando; Akito Hata; Haruyasu Murakami; Takahiro Kawakami; Katsuhiko Nagase; Kenichi Yoshimura; Tadami Fujiwara; Azusa Tanimoto; Akihiro Nishiyama; Sachiko Arai; Koji Fukuda; Nobuyuki Katakami; Toshiaki Takahashi; Yoshinori Hasegawa; Tun Kiat Ko; S Tiong Ong; Seiji Yano
Journal:  Cancer Sci       Date:  2020-01-06       Impact factor: 6.716

9.  Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.

Authors:  Yu-Bo Zhou; Yang-Ming Zhang; Hong-Hui Huang; Li-Jing Shen; Xiao-Feng Han; Xiao-Bei Hu; Song-da Yu; An-Hui Gao; Li Sheng; Ming-Bo Su; Xiao-Li Wei; Yue Zhang; Yi-Fan Zhang; Zhi-Wei Gao; Xiao-Yan Chen; Fa-Jun Nan; Jia Li; Jian Hou
Journal:  Acta Pharmacol Sin       Date:  2021-08-02       Impact factor: 6.150
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.